Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.16
▲ $0.01 (+0.9%)
Market data updated: 09/20 01:22 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$30.92M
Day Range
$1.11 - $1.21
52-Week Range
$0.71 - $3.40
Beta
—
Next Earnings
02.11.2026
Support
$0.71
Resistance
$1.62
ABVC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-57.4% (1Y)
Strengths: 12/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.07
Risk
Biggest negative driver
Operating margin
Operating margin: -2416.0% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
11d ago · $1.06
Evidence: FOMO score jumped from 20 to 58 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
47
Value
50
Momentum
72
Risk
32
Sentiment
80
Fundamental
20
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **ABVC BioPharma, Inc.** has primarily focused on its planned spin-off of **BioKey (Cayman), Inc.**—first announced in June 2026 as a dividend distribution to shareholders, then postponed in August 2026 before being rescheduled for August 21, 2026. No other notable developments or financial performance updates were reported in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about ABVC BioPharma, Inc.. News trend score: 80. Reason: 5 of the last 7 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
61
🎯 Conviction (vs. Emotion)
21
Investors appear highly excited (61), but evidence of strong fundamental conviction is comparatively weak (21).
Psychology
100
Fundamentals
20
Technical
72
Valuation
50
The price rise has far outpaced the actual improvement in fundamental data.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price (3M)
-14%
Market Narrative
80
Fundamental Reality
21
Narrative Gap
+59
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
ABVC’s psychology is dominated by **loss aversion**, reflecting a 27.8% drop over three months and heightened trading activity. The **narrative gap** (+36) and deteriorating fundamentals (revenue down -0.4%, margins collapsing -14.9pp) suggest investors are clinging to outdated optimism, reinforcing confirmation bias. Meanwhile, **herding** is active as ABVC underperforms peers (-4.0% vs. -1.9%), but euphoria and panic remain muted due to neutral RSI (53) and stable volatility. The key question: *Will traders exit to lock losses, or will fading fundamentals deepen the narrative disconnect?*
Updated: 09/07/2026, 01:05 AM
What could change this?
🧠 Market Brain events driving this
📈 17D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Howard Marks (Market Cycle) — 60/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among the methodologies, with some seeing cautious optimism while others flag it as risky or overvalued. Charles Mackay and Howard Marks (Market Cycle) both score highly, suggesting the stock isn’t driven by irrational crowd behavior or market euphoria, and may still have room to run in a broader cycle. However, other value-oriented investors like Benjamin Graham (both Defensive and Enterprising) and Philip Fisher dismiss it outright, arguing the stock lacks the statistical cheapness or quality-growth traits they demand. Meanwhile, cyclical or risk-averse frameworks—such as Gerald Loeb, Walter Bagehot, and Samuel Nelson—warn of overbought conditions, liquidity risks, or stretched valuations, while growth-focused thinkers like Peter Lynch and Thorstein Veblen see it as speculative or lacking sustainable momentum. The middle ground, represented by Jack Schwager and Morgan Housel, reflects uncertainty, with neither framework leaning decisively toward buy or hold.
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 60
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 54
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 54
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 53
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 48
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 33
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 31
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 25
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 9
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 7
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 0
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 3 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-2416.0%
Net Margin
-2671.8%
EBITDA Margin
-2416.0%
ROE
-71.2%
ROA
-37.5%
ROIC
—
EPS
-$0.39
Cash
$681.48K
Total Debt
$755.51K
Current Ratio
0.41
Debt/Equity
0.07
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$0.55
Tangible Book Value per Share (Tangible NAV)
$0.55
Sentiment based on basic keywords (not AI) — 5 positive, 2 neutral, 0 negative out of the last 7 articles.
ChartMill · 10.9.2026
Benzinga · 2.9.2026
Benzinga · 31.8.2026
Benzinga · 28.8.2026
Benzinga · 27.8.2026
Benzinga · 12.8.2026
NewMediaWire · 23.6.2026
ABVC BioPharma, Inc. (ABVC) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ABVC currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ABVC's technical score is 72/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.07; Price is above the 50-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: Operating margin: -2416.0% (negative); Net margin: -2671.8% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for ABVC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 7 purchases and 0 sales out of the last 18 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Stolz Kevin Patrick | Grant/Award from Employer | 27.1.2012 | 6,250 | +6,250 | — |
| Krotine Frank Thomas | Grant/Award from Employer | 25.5.2011 | 300,000 | +300,000 | $0.20 |
| Ramsey Sally Judith | Grant/Award from Employer | 11.5.2011 | 2,100,000 | +2,100,000 | $0.20 |
| Crockett Robert G | Grant/Award from Employer | 11.5.2011 | 1,800,000 | +1,800,000 | $0.20 |
| IANNOTTI DANIEL V | Grant/Award from Employer | 11.5.2011 | 300,000 | +300,000 | $0.20 |
| Stolz Kevin Patrick | Grant/Award from Employer | 11.5.2011 | 50,000 | +50,000 | $0.20 |
| Juliano James | Grant/Award from Employer | 12.8.2010 | 100,000 | +100,000 | $0.10 |
| Nirta Joseph | Open Market Purchase | 11.5.2010 | 10,000 | +10,000 | $0.15 |
| Nirta Joseph | Open Market Purchase | 22.3.2010 | 2,000 | +2,000 | $0.26 |
| Smith J.B. | Open Market Purchase | 13.1.2010 | 55 | +55 | $1,000.00 |
| Smith J.B. | Open Market Purchase | 16.12.2009 | 31 | +31 | $1,000.00 |
| Smith J.B. | Open Market Purchase | 13.11.2009 | 714,286 | +714,286 | $50,000.00 |
| Stromback Richard Dean | Open Market Purchase | 2.10.2009 | 14,400 | +14,400 | $0.42 |
| Stromback Richard Dean | Open Market Purchase | 1.10.2009 | 240 | +240 | $0.42 |
| Crockett Robert G | Grant/Award from Employer | 21.9.2009 | 670,000 | +670,000 | $0.51 |
| IANNOTTI DANIEL V | Grant/Award from Employer | 21.9.2009 | 70,000 | +70,000 | $0.51 |
| Krotine Frank Thomas | Grant/Award from Employer | 21.9.2009 | 169,000 | +169,000 | $0.51 |
| Nirta Joseph | Grant/Award from Employer | 20.10.2008 | 100,000 | +100,000 | $1.04 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
525,025 shares short as of 2026-08-31 · vs. 441,768 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
45.4% of trading volume this week was short selling, vs. 47.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology